United States Next Generation Sequencing Market Report by Product, Application, Technology, State and Companies Analysis 2026-2034

United States Next-Generation Sequencing Market Size & Forecast, 2026-2034

The United States Next Generation Sequencing market is projected to grow at a significant rate, driven from US$ 4.62 billion in 2025 to US$ 20.23 billion in 2034, at a compound annual growth rate of 17.83% from 2026-2034. The market is fueled mostly due to the adoption of precision medicine, the application of next-generation sequencing in oncology and genetic diagnostics for rare diseases, advances in sequencing technologies, and investment in genomics research.

Next Generation Sequencing in the USA: Market Analysis

Next-Generation Sequencing (NGS), also known as Next-Gen Sequencing or second-generation sequencing, is a highly advanced genomic solution for fast and efficient sequencing of both DNA and RNA molecules. Unlike the older sequencing techniques, NGS technology is capable of simultaneously analyzing millions of DNA/RNA fragments for the generation of whole-genome or targeted gene expression data in a relatively fast and cost-effective manner.

Being one of the fastest-growing genomics research and diagnostic platforms globally, Next-Gen Sequencing is applied in various domains like cancer genomics research, rare disease diagnostics, pathogen discovery for infectious diseases, fertility treatments and research, and drug discovery analysis and development for various diseases.

In the USA, the adoption of Next Generation Sequencing has been generating substantial interest due to the favorable environment that prevails. The USA is at the forefront of research involving genomics and has widespread adoption of NGS at institutions of higher learning, research laboratories, pharmaceutical companies, and bio-tech companies. The rise of personalized medicine practices and widespread cancer screening initiatives are some of the factors that have promoted its uptake.

Growth Driver in the United States Next Generation Sequencing Market

Increased Utilization of Precision Medicine

The US Next Generation Sequencing market is heavily influence by the growing adoption of precision medicine. NGS allows for comprehensive genetic characterization, making it suitable for personalized medicine, especially in cancer, rare diseases, and inherited conditions. Healthcare professionals increasingly analyze genomic information to pinpoint mutations, target therapy, and predict drug response. Precision Medicine programs at the national level and large-scale sequencing projects are rapidly integrating NGS into healthcare practices. Pharmaceutical organizations also benefit from NGS-based development of companion diagnostics and characterization of patients in advanced clinical trials. With the growing adoption of personalized medical practices across the US healthcare landscape, the growing demand for high-throughput, cost-effective, and high-quality sequencing platforms can also be seen. Nov 2025, Precision Medicine Group (Precision), a world-leading service provider in next-generation drug development, CRO, and commercialization, announced the launch of Institute Precision, a global expert networking forum where Precision scientists, medical professionals, regulators, commercial leaders, clients, and global biopharma experts come together to jointly consider the most challenging questions in the field of biopharma.

World-Class Research Infrastructure - Funded Research, Genomics

The United States has one of the best genomics research infrastructure systems globally, thanks to public and private investments in the field. Government agencies, academicians, and biotech firms invest significantly in genomics, population studies, and translating the results of genomics into medicine. NGS finds wide applications in cancer research, infectious disease monitoring, and functional genomics analyses. Extensive investments are being made in the technologies to ensure constant innovation and adoption at the market level. February 2025: Foundation Medicine has announced the launch of two new germline tests, FoundationOne Germline and FoundationOne Germline More, in the United States, which would detect the genetic changes connected with inherited cancers for healthcare providers to understand the underlying conditions faced by the patients and families affected by the cancers.

TECHNOLOGICAL PROGRESSION AND REDUCTIONS IN SE

Rapid innovations in technology are also contributing immensely to the U.S. NGS market. Innovations in the area of sequencing chemistry, automation, and bioinformatics analyses have led to greater accuracy, faster run times, and the ability to handle more samples with reduced prices. This has widened the applications of NGS technology, shifting from research to various clinical diagnostics. The emergence of bench-top, even more compact, sequencers is also facilitating remote testing in the hospital or clinical laboratory setting. Lower prices and better accessibility are continually fueling further expansion of the market. The month of January, 2024, saw the U.S. release of the LightSpeed-fortified CLC Genomics Workbench, QIAGEN Digital Insights.

Challenge in United States Next Generation Sequencing Market

Complexity in Data Management and Interpretation

NGS produces massive amounts of genomic data, which is complex to analyze using current bioinformatics infrastructure. A number of healthcare facilities are challenged by data storage and integration. Additionally, the lack of bioinformaticians and genetic counselors makes things worse and raises healthcare costs for patients. Such factors could act as barriers for smaller laboratories and hospitals in adopting NGS.

Regulatory and Reimbursement

Uncertainty Approval and reimbursement processes for NGS tests in the US may be challenging and inconsistent. Lack of consistency in reimbursement policies between public and private insurers creates fiscal uncertainty for diagnostic laboratories. Adherence to these dynamic regulations heightens the cost of development and places a delay in commercializing new tests.

United States Next Generation Sequencing Instruments Market

The United States market for NGS sequencing instruments is fueled by the demand for these products in research, clinical, and pharma applications. High throughput and bench-top sequencing platforms find a considerable level of usage for applications like cancer research, infectious disease testing, and whole genome sequencing. Upgrades and innovations in the technologies enable sustained market growth.

United States Next-Generation Sequencing Services Market

NGS services are finding greater favor among those who wish to escape high capital investment. NGS and data interpretation services are being offered to those who wish to carry out clinical trials and researches. The outsourcing trend that is being seen among the pharmaceutical companies is creating demand within this market.

United States Next-Generation Sequencing Diagnostics Market

NGS-based diagnostics are commonly used for cancer characterization, rare disease diagnosis, prenatal screening, and infectious disease identification. The growing acceptance from the clinical community, expanded test menus, and favorable reimbursement coverage for certain indications are contributing to the market growth in this category.

United States Drug Discovery Next Generation Sequencing Market

The United States drug discovery Next Generation Sequencing (NGS) market is growing rapidly because of the increasing need for faster, more precise, and cost-effective drug development. NGS is an essential component of target identification, biomarker research, pharmacogenomics, and the development of companion diagnostics. The pharmaceutical and biotech industry is primarily utilizing NGS to investigate genetic differences, disease mechanisms, and drug action, leading to more enlightened decisions in the preliminary research and development and clinical testing phases. The established dominance of major biotech firms, Contract Research Organizations (CROs), and research institutions is fueling widescale adoption. Moreover, rising investment in precision medicine and biologics development is further fueling the growth of the NGS drug discovery platform market.

United States Next Generation Sequencing by Synthesis Market

Sequencing by synthesis currently leads the U.S. NGS market on account of its ability to provide a high degree of accuracy and scalability. In addition, it can also be applied to a variety of applications. It is currently the most widely used technology for whole-genome sequencing, whole-exome sequencing, RNA sequencing, and targeted gene sequencing. Sequencing by synthesis is currently the most widely accepted technology in both research and medical institutions, as it is capable of providing high-quality results and high-throughput output. Furthermore, recent advancements in sequencing by synthesis technology, including improved automated instrumentation and bioinformatics, have enabled improved work flow and greater cost-effectiveness. This has made sequencing by synthesis the most prominent and commercially successful NGS technology in the United States.

United States Next Generation Ion Semiconductor Sequencing Market

Ion semiconductor sequencing is emerging as a rapidly growing market for targeted, rapid genome sequencing within the U.S. NGS market. This technology-based platform measures the hydrogen ions evolved during the GATC complementation reaction of DNA synthesis. This approach inhibits the need for optical detection systems, causing the run times for the platform to be shorter, with reduced complexity. These aspects give the platform preference for clinical labs, smaller institutions, or environments where rapid turnaround is required, such as for infectious disease testing or cancer panels. As for the market in the United States, the ion semiconductor technology market is emerging, favoring the more rapid, cost-efficient environment for the target segments of the U.S. NGS market. While its market share is smaller than the SBS market, innovations in this technology remain driven by the growing clinical uses.

United States Next Generation Sequencing Hospitals and Clinics Market

The hospitals and clinics segment is also becoming a very significant end-user group for the NGS industry as genomics analysis starts being mainstream across the US health industry. NGS analysis has widespread adoption across hospitals for handling cancer profiles, rare diseases, prenatal diagnosis, and infectious diseases. The recent trend for precision medicine has prompted hospitals and health centers to either set up their own NGS facilities or opt for a third party for the service. Improvements in benchtop sequencers and automated systems are increasingly making NGS technology more acceptable and easily accessible to hospitals and laboratories. The current presumed reimbursement for certain genetic tests and intensifying physician awareness are also positively contributing to NGS adoption by hospitals and health centers, and the trend for mainstream NGS adoption across US hospitals is expected to continue steadily.

California Next Generation Sequencing Market

California is a representation of one of the most evolved and vibrant Next Generation Sequencing markets in the United States. There are a large number of biotech firms, research institutions, and genetic research facilities concentrated in the state, specifically in areas like the Bay Area around San Francisco and San Diego. Furthermore, increased spending in the life sciences arena combined with early adoption of innovative technology has enabled widespread usage of Next Generation Sequencing in areas like cancer research, rare diagnostics, and drug development. There is substantial venture capital spending in addition to government-sponsored research grants that help facilitate large-scale genetic projects in California. Hospitals and clinical labs are increasingly adopting Next Generation Sequencing in their daily diagnostics practices in areas like oncology and inherited diseases.

New York Next Generation Sequencing Market

New York is an important hub for the adoption of Next Generation Sequencing due to the robust academic, medical, and research environment that exists within the region. New York state has the best medical facilities in the world, which are engaged actively in the utilization of NGS in the field of precision medicine, oncology diagnostics, and translation research on a large scale. Also, the state has large patient populations within medical facilities and other settings, which helps in conducting large-scale genomic studies for the improvement of population health. Further, the healthcare system in New York state embraces the utilization of NGS on a large scale, including tumor analysis, prenatal screening, and rare disease diagnostics.

Next Generation Sequencing Market in New Jersey

The New Jersey market is also significant for the overall NGS industry in the United States owing to the presence of large numbers of pharmaceuticals, biotech, and life sciences companies there. New Jersey is also associated with prominent healthcare and research centers in the Northeastern part of the United States, thus aiding in better collaboration and adoption of technology. The NGS technology is widely utilized in New Jersey for discovering drugs, identifying biomarkers, conducting clinical trials, and the development of companion diagnostics. The hospitals and diagnostic labs are increasingly adopting NGS for cancer analysis and genetic disease screening. Furthermore, easy access to regulatory authorities is also aiding in innovation in this technology.

Texas Next Generation Sequencing Market

Texas represents one of the fastest-growing regions for Next Generation Sequencing in the US. Factors contributing to the adoption of advanced genome technology include the growing population, improving modes of care, and the rising incidence of cancers and genetic diseases in the country. Texas has incorporated advanced research facilities, leading medical institutions, and biotechnology companies in major cities including Houston, Dallas, and Austin, which utilize NGS technology for their diagnostic, research, and biotechnological applications. Texas has observed significant investments in genomics and biotechnology for the better adoption of genome technology. Hospitals and laboratories are increasingly adopting NGS for the detection of cancers, infectious diseases, and inherited diseases in Texas.

Market Segmentations

Product

• Instruments
• Reagents & Consumables
• Services

Application

• Diagnostics
• Agriculture and Animal Research
• Drug Discovery
• Personalized Medicine and Genetic Screening
• Others

Technology

• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Single Molecule Read Time Sequencing
• Nanopore Sequencing
• Others

End User

• Academic and Clinical Research Centers
• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Others

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences
• QIAGEN N.V
• Roche
• Bio-Rad Laboratories, Inc.
• Takara Bio Inc.
• Hamilton Company
• Geneious
• BioMerieux SA